XENON PHARMACEUTICALS INC (XENE) Fundamental Analysis & Valuation

NASDAQ:XENE • CA98420N1050

Current stock price

55.03 USD
-0.5 (-0.9%)
Last:

This XENE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. XENE Profitability Analysis

1.1 Basic Checks

  • In the past year XENE has reported negative net income.
  • In the past year XENE has reported a negative cash flow from operations.
  • In the past 5 years XENE always reported negative net income.
  • XENE had a negative operating cash flow in each of the past 5 years.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • XENE has a Return On Assets of -54.63%. This is comparable to the rest of the industry: XENE outperforms 44.70% of its industry peers.
  • The Return On Equity of XENE (-59.46%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.63%
ROE -59.46%
ROIC N/A
ROA(3y)-34.3%
ROA(5y)-26.59%
ROE(3y)-36.72%
ROE(5y)-28.3%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • XENE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. XENE Health Analysis

2.1 Basic Checks

  • XENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • XENE has more shares outstanding than it did 1 year ago.
  • XENE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • XENE has an Altman-Z score of 56.09. This indicates that XENE is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 56.09, XENE belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
  • There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 56.09
ROIC/WACCN/A
WACC8.23%
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • XENE has a Current Ratio of 13.42. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 13.42, XENE belongs to the best of the industry, outperforming 89.02% of the companies in the same industry.
  • XENE has a Quick Ratio of 13.42. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 13.42, XENE belongs to the top of the industry, outperforming 89.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.42
Quick Ratio 13.42
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. XENE Growth Analysis

3.1 Past

  • The earnings per share for XENE have decreased strongly by -44.37% in the last year.
  • Measured over the past years, XENE shows a very negative growth in Revenue. The Revenue has been decreasing by -25.27% on average per year.
EPS 1Y (TTM)-44.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.95%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-7.35%
Revenue growth 5Y-25.27%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 21.93% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, XENE will show a very strong growth in Revenue. The Revenue will grow by 170.94% on average per year.
EPS Next Y-12.93%
EPS Next 2Y-1.38%
EPS Next 3Y14.4%
EPS Next 5Y21.93%
Revenue Next Year-42.77%
Revenue Next 2Y280.99%
Revenue Next 3Y247.4%
Revenue Next 5Y170.94%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. XENE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XENE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XENE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • XENE's earnings are expected to grow with 14.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.38%
EPS Next 3Y14.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XENE Dividend Analysis

5.1 Amount

  • XENE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XENE Fundamentals: All Metrics, Ratios and Statistics

XENON PHARMACEUTICALS INC

NASDAQ:XENE (3/27/2026, 2:36:51 PM)

55.03

-0.5 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners104.28%
Inst Owner Change-0.25%
Ins Owners0.07%
Ins Owner Change0.49%
Market Cap5.08B
Revenue(TTM)7.50M
Net Income(TTM)-345.91M
Analysts87.41
Price Target56.49 (2.65%)
Short Float %6.74%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.83%
Min EPS beat(2)-7.8%
Max EPS beat(2)2.13%
EPS beat(4)2
Avg EPS beat(4)-0.18%
Min EPS beat(4)-7.8%
Max EPS beat(4)10.75%
EPS beat(8)5
Avg EPS beat(8)1.2%
EPS beat(12)8
Avg EPS beat(12)2.82%
EPS beat(16)10
Avg EPS beat(16)2.12%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.64%
PT rev (3m)0.54%
EPS NQ rev (1m)-5.26%
EPS NQ rev (3m)-5.26%
EPS NY rev (1m)-2.19%
EPS NY rev (3m)-2.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-18.61%
Revenue NY rev (3m)-18.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 676.87
P/FCF N/A
P/OCF N/A
P/B 8.73
P/tB 8.73
EV/EBITDA N/A
EPS(TTM)-4.36
EYN/A
EPS(NY)-4.92
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS0.08
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.63%
ROE -59.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.3%
ROA(5y)-26.59%
ROE(3y)-36.72%
ROE(5y)-28.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.42%
Cap/Sales 10.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.42
Quick Ratio 13.42
Altman-Z 56.09
F-Score4
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)141.36%
Cap/Depr(5y)165.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.95%
EPS Next Y-12.93%
EPS Next 2Y-1.38%
EPS Next 3Y14.4%
EPS Next 5Y21.93%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-7.35%
Revenue growth 5Y-25.27%
Sales Q2Q%N/A
Revenue Next Year-42.77%
Revenue Next 2Y280.99%
Revenue Next 3Y247.4%
Revenue Next 5Y170.94%
EBIT growth 1Y-33.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.92%
EBIT Next 3Y5.95%
EBIT Next 5Y24.32%
FCF growth 1Y-51.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.88%
OCF growth 3YN/A
OCF growth 5YN/A

XENON PHARMACEUTICALS INC / XENE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of XENON PHARMACEUTICALS INC (XENE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to XENE.


Can you provide the valuation status for XENON PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to XENON PHARMACEUTICALS INC (XENE). This can be considered as Overvalued.


Can you provide the profitability details for XENON PHARMACEUTICALS INC?

XENON PHARMACEUTICALS INC (XENE) has a profitability rating of 1 / 10.


How financially healthy is XENON PHARMACEUTICALS INC?

The financial health rating of XENON PHARMACEUTICALS INC (XENE) is 8 / 10.